Tsuchihashi T, Yamaguchi K, Miyake Y, Otsubo K, Nagasaki K, Honda S, Akiyama Y, Maeda Y, Koike M, Alper O
Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan.
J Natl Cancer Inst. 1990 Jan 3;82(1):40-4. doi: 10.1093/jnci/82.1.40.
We assessed the relationship between the parathyroid hormone-related protein (PTHrP) and the development of humoral hypercalcemia of malignancy (i.e., hypercalcemia due to the production by solid tumors of hypercalcemic factors) by assaying tumor extracts from hypercalcemic and normocalcemic patients with cancer for immunoreactive PTHrP contents. Immunoreactive PTHrP was demonstrated in extracts of 21 of 22 tumor tissues obtained from 22 patients with humoral hypercalcemia of malignancy. Immunoreactive PTHrP was rarely seen in tumor tissue extracts obtained from 34 normocalcemic patients with cancer and two hypercalcemic patients with cancer with severe bone metastases. Gel filtration studies of tumor extracts revealed a molecular-size heterogeneity of immunoreactive PTHrP. These radioimmunoassay data indicate a close relationship between detection of PTHrP in tumor tissues and the development of humoral hypercalcemia of malignancy.
我们通过检测高钙血症和血钙正常的癌症患者的肿瘤提取物中免疫反应性甲状旁腺激素相关蛋白（PTHrP）的含量，评估了PTHrP与恶性肿瘤体液性高钙血症（即实体瘤产生高钙血症因子导致的高钙血症）发生之间的关系。在22例恶性肿瘤体液性高钙血症患者的22个肿瘤组织提取物中，有21个检测到免疫反应性PTHrP。在34例血钙正常的癌症患者以及2例伴有严重骨转移的高钙血症癌症患者的肿瘤组织提取物中，很少见到免疫反应性PTHrP。肿瘤提取物的凝胶过滤研究显示免疫反应性PTHrP存在分子大小异质性。这些放射免疫分析数据表明，肿瘤组织中PTHrP的检测与恶性肿瘤体液性高钙血症的发生密切相关。
